199447-10-4

Usage

Uses

Used in Chemical Synthesis:
3-[(Hydroxyamino)iminoMethyl]-Benzoic Acid is used as a building block in chemical synthesis for creating a variety of complex organic molecules. Its reactivity and functional groups make it a versatile component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used as a Reagent in Organic Reactions:
In the realm of organic chemistry, 3-[(Hydroxyamino)iminoMethyl]-Benzoic Acid serves as a reagent that can participate in various types of chemical reactions, such as condensation, substitution, and rearrangement reactions. Its presence can alter the course of a reaction or improve the yield of desired products.
Used in Research and Development:
3-[(Hydroxyamino)iminoMethyl]-Benzoic Acid is utilized in research and development for exploring new chemical pathways and understanding reaction mechanisms. Its unique structure and reactivity make it a valuable tool for probing the limits and possibilities of organic synthesis.
Used in Chelating Applications:
3-[(Hydroxyamino)iminoMethyl]-Benzoic Acid is used as a chelating agent in various industrial processes. Its ability to form coordinate bonds with metal ions is particularly useful in applications such as water treatment, where it can help remove heavy metals, and in the purification of metal ions in chemical processes.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 3-[(Hydroxyamino)iminoMethyl]-Benzoic Acid may be employed as a precursor or intermediate in the development of new drugs. Its chemical properties could contribute to the creation of novel therapeutic agents with unique mechanisms of action.
Used in Material Science:
3-[(Hydroxyamino)iminoMethyl]-Benzoic Acid can be incorporated into the development of new materials with specific properties, such as sensors, catalysts, or advanced polymers. Its ability to chelate metal ions could be particularly useful in creating materials with tailored electronic or catalytic properties.

InChI:InChI=1/C8H8N2O3/c9-7(10-13)5-2-1-3-6(4-5)8(11)12/h1-4,13H,(H2,9,10)(H,11,12)/p-1

Upstream product

• 1877-72-1 3-Cyanobenzoic acid 
• 52820-49-2 3-Amidinium benzoate 

Downstream Products

• 264264-32-6 3-(5-methyl-[1,2,4]-oxadiazol-3-yl)benzoic acid 
• 1092566-65-8 methyl 3-(5-methyl-1,2,4-oxadiazol-3-yl)benzoate 
• 42823-63-2 3-amidinobenzoic acid hydrochloride 
• 775304-57-9 ataluren 
• 1314891-22-9 (N-(2-methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide) 
• 1314890-39-5 N-((4-(4-phenylthiophen-2-yl)tetrahydro-2H-pyran-4-yl)methyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide 
• 1314890-36-2 1-(4-(4-phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)-N-(3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)methanamine 
• 1314890-63-5 N-(2-(4-(4-fluorophenyl)thiazol-2-yl)-2-methylpropyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide 
• 1314890-57-7 N-((4-(4-(pyridin-2-yl)thiazol-2-yl)tetrahydro-2H-pyran-4-yl)methyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide 
• 1314891-23-0 2-(2-(4-fluorophenyl)oxazol-4-yl)-2-methyl-N-(3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzyl)propan-1-amine 
• 1314890-44-2 N-((4-(2-phenylthiazol-4-yl)tetrahydro-2H-pyran-4-yl)methyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide 
• 1314891-59-2 N-(2-(4-(4-fluorophenyl)thiazol-2-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide 
• 1314890-43-1 N-((4-(3-phenyl-1H-1,2,4-triazol-5-yl)tetrahydro-2H-pyran-4-yl)methyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide 
• 1092400-82-2 3-(5-(trifluoromethyl)-1,2,4–oxadiazol–3–yl)benzoic acid 

Relevant academic research and scientific papers

PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES

The present invention provides processes for the preparation of ataluren. Intermediates for preparing ataluren are also provided.

Novel method for synthesizing Ataluren

The invention discloses a novel method for synthesizing Ataluren. The method comprises the following steps that 1, a compound 2 reacts with hydroxylamine hydrochloride under the alkaline condition to obtain an intermediate 3; 2, in the presence of a reducing agent diethoxymethylsilane and bis(4-nitrobenzophenone)phosphate, a catalytic amount of triphenylphosphine and an equivalent amount of carbon tetrachloride and compound 4 react to obtain the target compound Ataluren (1). According to the method, the raw materials are easy to obtain, the synthesizing steps are brief, environmental friendliness is achieved, aftertreatment is convenient, and high industrial production value is achieved.

METHODS OF USE OF A CLASS llA HDAC INHIBITOR

Novel uses of selective class Ila HDAC inhibitors are described.

Optical film, retardation plate, elliptica polarizing plate, liquid crystal display device and compound

An optical film including at least one compound represented by formula (1) is disclosed. In the formula, Y11, Y12 and Y13 each independently represent methine or a nitrogen atom; R11, R12 and R13

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

COMPOUNDS AND METHODS

Disclosed are compounds having formula I, wherein X1, X2, X3, R1, R2, R3, R4, R5, Y, A, Z, L, m and n are as defined herein, and methods of making and using the same.

Conformationally restricted analogs of the direct thrombin inhibitor FM 19

The serine protease thrombin plays several key roles in the clotting cascade within the hemostatic system, such as in fibrin formation and platelet activation. Thus, development of an inhibitor that binds to the enzyme's active site (a direct thrombin inhibitor) offers an approach for the treatment of thrombus-associated diseases. Previous structure-activity relationship studies originally based on the bradykinin breakdown product Arg-Pro-Pro-Gly-Phe (RPPGF) led to the development of lead compound FM 19 (d-Arg-Oic-Pro-d-Ala-Phe(p-Me)- NH2). The recently determined X-ray structure of FM 19 in the active site of thrombin has revealed sites of modification to potentially improve inhibition. In this study, we report the synthesis and biological characterization of nine peptides that replace only the d-Arg residue of the FM 19 sequence, investigating ways to add conformational restriction, modification of the basic moiety at the end of the side chain, and removal of the charge from the N-terminus. Two of these peptides, 6 and 7 (IC50 values of 0.51 and 0.45 μM, respectively), show similar potency to the best compounds in the FM 19 series reported thus far.

Pyridazinone derivatives

Compounds of the formula (I) in which D, R1, R2, R3, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment

BENZOTHIAZOLONE DERIVATIVES

Compounds of the formula I, in which R1, R2, R3, R3′, R4, R4′, E, E′, E″ and E′″ have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and ca

2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS

Compounds of the formula (I), in which R1, R2, R3, R3′, R4, R4′, E, E′, E″ and E′″ have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.